Sbir phase II R & D
Ended Awarded Last action
- Contract number
- N6833521F0315
- Awardee
-
Autonomous Therapeutics Inc. UEI JFHPX6TUYMU8
- Awarding agency
-
Naval Air Warfare Center
Naval Air Systems Command, Department of Defense
- Obligated
- $1,625,896
Award facts
- Contract value 100% obligated
- $1,625,895.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- North Bethesda, MD 20852, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $625,905 | |
| Original award | $999,991 |
About this award
Autonomous Therapeutics Inc., a small biotechnology firm headquartered in Silver Spring, Maryland, received a $1.63M Small Business Innovation Research (SBIR) Phase II contract from the Naval Air Warfare Center, a defense agency within the Department of the Navy, under a total small business set-aside designation. The contract, awarded on May 7, 2021, with completion targeted for November 30, 2023, was structured as a delivery order with cost-plus-fixed-fee pricing and included research and development work to be performed at the company's Rockville, Maryland facility. As a Phase II SBIR award, this contract represented a continuation and expansion of earlier Phase I research, aimed at developing innovative technology solutions to support naval aviation objectives.
The SBIR Phase II program, managed by the Small Business Administration in partnership with federal agencies, provides funding to small businesses to conduct research and development with commercial potential and national defense relevance. Autonomous Therapeutics' expertise in antiviral therapeutics and RNA-based technology platforms aligned with the Naval Air Warfare Center's innovation priorities. This contract exemplifies the SBIR program's role in fostering technological advancement through small business partnerships, enabling the company to further develop and refine its research capabilities while addressing specific naval technology requirements within the established contract ceiling.
Quick answers
Who was awarded contract N6833521F0315?
N6833521F0315 was awarded to Autonomous Therapeutics Inc. by Naval Air Warfare Center (Naval Air Systems Command) on May 7, 2021.
How much is contract N6833521F0315 worth?
The government has obligated $1,625,896 on N6833521F0315.
Is contract N6833521F0315 an order under another contract?
Yes. N6833521F0315 is a delivery order under N6833521G0017, a basic ordering agreement.
Was contract N6833521F0315 competed?
The extent of competition for N6833521F0315 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award